Drug Trial Radar · NCT05695521
Regulatory T Cells for Amyotrophic Lateral Sclerosis
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Apr 3, 2023
Primary completion
May 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Cellenkos, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 95 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells in additional 60 patients with Amyotrophic Lateral Sclerosis.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
CK0803Biological
CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously
ExcipientOther
Excipient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Limiting Toxicity (TLT)Time frame: 28 days
- Combined assessment of function and survival (CAFS)Time frame: 24 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Columbia University Irving Medical Center
New York, New York
Baylor College of Medicine
Houston, Texas
Michael E. DeBakey Veterans Affairs Medical Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.